Jon Faldasz/LinkedIn
Nov 21, 2025, 08:55
Jon Faldasz: Why Aren’t We Better at Achieving Therapeutic Warfarin Control?
Jon Faldasz, Senior Director of Product and Customer Experience at InsightRX, posted on LinkedIn:
”Ok I know warfarin is the stinky kid in the corner, but it’s not going anywhere. So why aren’t we better at achieving time in therapeutic range?
Could it be:
– We think that 40% time in range is “good enough”? (data argues otherwise)
– Low warfarin use means we think this problem isn’t significant (patients would argue otherwise)
– We think that the problem is unsolvable? (Anticoagulation specialists argue otherwise)
I would love to get some comments to bring with me to the Anticoagulation Forum Stewardship Summit. Don’t make me call you out, people.”

Stay updated with Hemostasis Today.
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026
-
Jul 14, 2026, 12:02Louise St. Germain Bannon: Our first ISTH regulatory session at ISTH 2026
-
Jul 14, 2026, 11:21Malwina Maliszewska: Advancing Coagulation Diagnostics at ISTH 2026
-
Jul 14, 2026, 11:07Mary Cushman: Honoring Outstanding Mentorship at ISTH 2026
-
Jul 14, 2026, 10:53Maha Othman: Advancing the Management of Inherited Thrombocytopenias at ISTH 2026
-
Jul 14, 2026, 10:24Sara Zalghout: The Little Things That Make ISTH 2026 Special
-
Jul 14, 2026, 10:11Joseph R. Shaw: GAUGE Advances FXa Inhibitor Reversal at ISTH 2026
-
Jul 13, 2026, 23:39Yaariv Khaykin: Whole-Person Care Can Strengthen Stroke Prevention in Patients With Atrial Fibrillation